DOCSLIB.ORG

NUMER 6.Vp:Corelventura

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NUMER 6.Vp:Corelventura Copyright © 2004 by Institute of Pharmacology Polish Journal of Pharmacology Polish Academy of Sciences Pol. J. Pharmacol., 2004, 56, 755766 ISSN 1230-6002 SYNTHESIS AND CARDIOVASCULAR ACTIVITY OF NEW 8-ALKYLAMINO-1,3-DIMETHYL-7-(2-HYDROXY-3-PIPERAZI- NOPROPYL)-3,7-DIHYDRO-1H-PURINE-2,6-DIONES Gra¿yna Ch³oñ-Rzepa1, Maciej Paw³owski1,#, Ma³gorzata Zygmunt2, Barbara Filipek2, Dorota Maci¹g2 Department of Pharmaceutical Chemistry, Department of Pharmacodynamics, Laboratory of Pharmacological Screening, Collegium Medicum, Jagiellonian University, Medyczna 9, PL 30-688 Kraków, Poland Synthesis and cardiovascular activity of new 8-alkylamino-1,3-dimethyl- -7-(2-hydroxy-3-piperazinopropyl)-3,7-dihydro-1H-purine-2,6-diones. G. CH£OÑ- -RZEPA, M. PAW£OWSKI, M. ZYGMUNT, B. FILIPEK, D. MACI¥G. Pol. J. Pharmacol., 2004, 56, 755–766. 7-{2-Hydroxy-3-[4-(2-phenoxyethyl)-piperazinyl-1-yl]-propyl}-1,3-di- methyl-3,7-dihydro-1H-purine-2,6-dione dihydrochloride (2), and several of its 8-alkylamino substituted derivatives (11–17) were synthesized and tested for electrocardiographic, antiarrhythmic and hypotensive activity. Also their a- and a -adrenoreceptor affinities were determined. It was found that com- pound 2, and its analogue 15 with 8-(2-morpholin-4-yl-ethylamino) substitu- ent displayed a strong prophylactic antiarrhythmic activity in experimentally induced arrhythmia (LD#/ED# = 54.9 and 55.0, respectively). The hypoten- sive activity was observed for 8-benzylamino (11) or 8-(pyridin-2-yl- methylamino) (12) analogues. All the new derivatives (11–17) and 2 showed a weak affinity for a-(KE = 0.225–1.400 mM) and a -(KE = 0.152–4.299 mM) receptors. Key words: purine-2,6-diones, antiarrhythmics, hipotensive agents, a- and a -receptor ligands correspondence;e-mail: [email protected] G. Ch³oñ-Rzepa, M. Paw³owskI, M. Zygmunt, B. Filipek, D. Maci¹g INTRODUCTION arrhythmic and hypotensive activity as well as for a1- and a2-adrenoreceptor binding affinities. Theophylline (1,3-dimethyl-3,7-dihydro-1H-pu- rine-2,6-dione) and a number of its salts and 7-sub- MATERIAL and METHODS stituted derivatives exhibit multidirectional phar- macological properties. Their activities such as CNS stimulation, peripherial smooth muscle re- Chemical part laxation (broncho- and vasodilatation) heart rate in- crease result from the antagonism at adenosine re- Melting points (m.p.) were determined with ceptors and non-selective inhibition of the cyclic a Büchi SMP-20 apparatus and are uncorrected. nucleotide phosphodiesterases [23]. These com- UV spectra were recorded on a Perkin Elmer Lambda 12 UV-VIS spectrometer in5×105 mol/l pounds are commonly used in the treatment of sev- 1 eral diseases such as asthma (theophylline, amino- methanolic solutions. H-NMR spectra (Mercury Varian BB 300 MHz NMR spectrometer) were de- phylline, etophylline, proxyphylline, diprophyl- termined in CDCl solution, with TMS as an inter- line), cardiac failure, and peripheral circulation 3 nal standard. Chemical shifts (d) are reported in disorders (xanthinol nicotinate). It was also found ppm, coupling constants (J) are given in Hz. Mass that pyrimidine-8-on[2,1-f] theophylline-9-alkylcarb- spectra (MS) were taken with a AMD-604 mass oxylic acids derivatives possess hypnotic, sedative spectrometer (EI mode, 70 eV). Thin-layer chro- and tranquillizing properties [4]. matography (TLC) was performed on Merck pre- In the course of our search for new biologically coated silica gel 60 F aluminium plates, using: active compounds belonging to the group of 7,8- 254 S : benzene/acetone/methanol (1:1:1, v/v/v); S : disubstituted theophylline derivatives, we have 1 2 methanol/25% NH3 (100:5, v/v) as mobile phases. found that 7-(2-hydroxypropyl)-8-benzylaminotheo- The spots were visualized under UV light (l = 254 phyllines exhibited hypotensive effects and re- nm) or by iodine solution (0.05 M in 10% HCl). duced heart rate, as well as stimulated respiratory Elemental analyses (C, H, N) were carried out with activity [12]. Pharmacological investigation of Elementar Vario EL III apparatus and were within 7-(2-hydroxy-3-alkylamino)-propyl derivatives of ± 0.4% of the theoretical values. 8-benzylaminotheophylline and 7-(2-hydroxy-3-al- The 1,3-dimethyl-7-oxiranylmethyl-3,7-dihy- kylamino)-propyl derivatives of 8-(2-furfurylami- dro-1H-purine-2,6-dione (1) [24] and 8-bromo- no)-theophylline, revealed also hypotensive and 7-(3-chloro-2-hydroxypropyl)-1,3-dimethyl-3,7-di- bronchodilatatory effects [5, 14, 15]. It is known hydro-1H-purine-2,6-dione (3) [3] were used as that aryl and arylalkyl substituted piperazines show starting materials for the synthesis of new com- a -adrenolytic, hypotensive and vasodilatatory ac- pounds 2 and 11–17. tivity [6, 16, 18, 20]. The described pharmacologi- Compound 2 was synthesized by aminolysis cal effects prompted us to synthesize new theophyl- of 1 with 1-(2-phenoxyethyl)-piperazine [13]. The line derivatives with 1-(2-phenoxyethyl)-piper- 8-alkylamino derivatives of 7-{2-hydroxy-3-[4-(2- azine moiety attached to theophylline nucleus as phenoxyethyl)-piperazin-1-yl]-propyl}-3,7-dihyd- potential agents acting on the cardiovascular sys- ro-1H-purine-2,6-dione (11–16) were obtained by tem. two step procedure (Scheme 1). Compound 3 in the In this paper, we report the synthesis as well as reaction with the appropriate aryl-(heteroaryl-, the results of pharmacological evaluation (in vivo morpholino- or diethylamino)-alkylamine gave in- and in vitro tests) of 7-{2-hydroxy-3-[4-(2-phen- termediate products, previously described 4 and 7 oxyethyl)-piperazin-1-yl]-propyl}-1,3-dimethyl-3,7- [14], and the new ones 5, 6, 8 and 9. In the second dihydro-1H-purine-2,6-dione dihydrochloride (2) step, compounds 4–9 heated with 1-(2-phe- and its 8-alkylamino analogues (11–16). In order to noxyethyl)-piperazine in anhydrous ethanol (for establish the role of the arylalkyl substituent at compounds 11, 12, 14, 16, 17) or toluene (for com- 8 position, the unsubstituted 8-amino analogue (17) pounds 13, 15) in the presence of anhydrous was also obtained. Compound 2 and the newly syn- K2CO3 yielded final products 11–16 (Scheme 1). thesized 11–17 in a form of water soluble hydro- The reaction of 3 with 25% NH3 in dioxane yielded chlorides were tested for electrocardiographic, anti- the intermediate product 10, which treated with 756 Pol. J. Pharmacol., 2004, 56, 755–766 CARDIOVASCULAR ACTIVITY OF NEW 8-ALKYLAMINO-PURINE-2,6-DIONES Cl O OH H C N 3 N Br O N N 3 CH3 H2N-(CH2)n-R 25% NH3 methanol dioxane Cl Cl O O OH OH H C N H C N 3 N 3 N NH NH (CH2)n R 2 O N N O N N 4-9 10 CH CH3 3 O O HN N HN N K CO , ethanol K2CO3, ethanol or toluene 2 3 O O N N N N O O H C OH H C 3 N 3 N OH N 17 N 11-16 NH NH (CH )n R 2 2 N O N N O N CH CH 3 3 No 4, 11 5, 12 6, 13 7, 14 8, 15 9, 16 C H R N O N 2 5 O C H N N 2 5 n1 1 2 1 2 2 Scheme 1. Synthesis of compounds 4–17 1-(2-phenoxyethyl)-piperazine yielded the final General procedure for preparation of the 8-al- 8-aminoderivative 17 (Scheme 1). kylamino derivatives of 7-(3-chloro-2-hydroxy Compounds 11–17 were isolated and examined propyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6- 1 as free bases for their H-NMR, MS and UV spec- dione (5-6, 8 and 9) tra as well as by elemental analyses. For pharma- cological studies the free bases 11–17 were con- verted into water soluble hydrochloride salts. The A solution of 3 (3.52 g, 0.01 mol) and appropri- salts were recrystallized and their composition was ate amine (0.02 mol) in methanol (40 ml) was established on the basis of an elemental analysis. heated under reflux for 5 h. Then the reaction mix- Yields and physicochemical properties of the ob- ture was cooled down. The precipitated solid prod- tained compounds (free bases and their salts) are uct was filtered off and purified by recrystallization presented in Table 1. from suitable solvent (Tab. 1). ISSN 1230-6002 757 G. Ch³oñ-Rzepa, M. Paw³owskI, M. Zygmunt, B. Filipek, D. Maci¹g Table 1. Physicochemical data of new compounds 5, 6 and 8–17 Comp. M.p. (°C) Yield (%) (base) Molecular formula (molecular RB (solvent system) Cryst. solvent weight)* Base Salt 5 171–172 52 C16H19N6O3Cl 0.88 (S1) methanol (378.8) 6 204–206 87 C17H21N6O3Cl 0.89 (S1) 2-methoxyethanol (392.8) 8 153–155 69 C16H25N6O4Cl 0.82 (S1) methanol (400.9) 9 147–149 71 C16H27N6O3Cl 0.43 (S2) methanol (386.9) 10 232–233 51 C10H14N5O3Cl 0.43 (S1) ethanol (287.7) 11 95–97 242–244 48 C29H37N7O4 ×2HCl×H2O 0.82 (S1) ethanol (638.6) 12 165–166 249–251 85 C28H36N8O4 × 3 HCl 0.58 (S1) ethanol (658.0) 13 140–142 180–185 75 C29H38N8O4 × 3 HCl 0.55 (S1) methanol (672.0) 14 118–120 231–233 55 C27H35N7O5 ×2HCl×H2O 0.80 (S1) methanol (628.5) 15 134–136 215–217 54 C28H42N8O5 × 3 HCl 0.15 (S1) acetone (680.0) 16 105–107 215–218 56 C28H44N8O4 ×3HCl×H2O 0.23 (S2) acetone (666.1) 17 154–156 262–264 56 C22H31N7O4 × 2 HCl × 1/2 H2O 0.33 (S1) ethanol (539.4) * calculated from elemental analysis 7-(3-Chloro-2-hydroxy-propyl)-1,3-dimethyl-8- CH3), 3.44 (s, 3H, N3-CH3), 3.51–3.70 (m, 2H, [(pyridin-2-yl-methyl)-amino]-3,7-dihydro-1H- NHCH2CH2), 3.77–3.90 (m, 2H, CH2Cl), 4.09–4.39 purine-2,6-dione (5) (m, 3H, N7-CH2,CHOH), 6.17 (t, 1H, NH), 7.14–7.18 (m, 1H, 5’pyridine), 7.23–7.25 (d, 1H, l e 1 UV: max (log ): 294 nm (4.26).
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0060381A1 Meier Et Al
    US 2003OO60381A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0060381A1 Meier et al. (43) Pub. Date: Mar. 27, 2003 (54) DISPERSION COMPRISING A NON-IONIC (30) Foreign Application Priority Data EMULSIFIER Mar. 10, 2000 (DE)..................................... 100 11447.4 (76) Inventors: Christian Meier, Darmstadt (DE); Johanna Eisele, Darmstadt (DE); Publication Classification Michael Schnabel, Biebesheim (DE); Klaus Schultes, Wiesbaden (DE); (51) Int. Cl." ....................................................... A61K 7/50 Stefan Grimm, Worms (DE); (52) U.S. Cl. ............................................ 510/141; 510/153 Hans-Ulrich Petereit, Darmstadt (DE); Thomas Suefke, Erzhausen (DE) (57) ABSTRACT Correspondence Address: The invention relates to a dispersion Suitable for use as OBLON, SPIVAK, MCCLELLAND, MAIER & coating agent and binder for pharmaceutical forms, having NEUSTADT, P.C. a solids content of 10-70% by weight consisting of 1940 DUKE STREET a) from 90 to 99% by weight of a methacrylate copolymer ALEXANDRIA, VA 22314 (US) consisting of at least 90% by weight of (meth)acrylate monomers containing neutral radicals and having a (21) Appl. No.: 09/926,484 glass transition temperature Tg of from -20°C. to +20 C. as determined by the DSC method, and (22) PCT Filed: Feb. 2, 2001 b) 1-10% by weight of a nonionic emulsifier having an (86) PCT No.: PCT/EP01/01108 HLB of from 15.2 to 17.3. Patent Application Publication Mar. 27, 2003. Sheet 1 of 2 US 2003/0060381 A1 E. CD E H 3 & 8 9 % eSeele Patent Application Publication Mar. 27, 2003. Sheet 2 of 2 US 2003/0060381 A1 E. C) H 33 S.
    [Show full text]
  • Approved Drug List,February 2018
    c Maldives Food and Drug Authority Ministry of Health Male’, Republic of Maldives Approved Drug List Number: MTG/RE-AL/Li 0009/2018-0001 Acronym Expansion Remarks R Registered product These are pharmaceutical products registered and approved with full dossier submission. Product safety, quality and efficacy has been evaluated based on the submitted documents and certificates of the manufacture and the product Once registered and approved, it is the Re Registered product which has responsibility of the marketing authorization holder to been given exclusivity under set provide all necessary information required and if there is any condition. change in the product/packaging etc., and to ensure that the product is available in the market. EA Exemption Approvals These are special approvals for importing pharmaceutical products based on minimum evaluation of safety and quality of the product with information of the imports and availability in the market of the same. This approval is a temporary approval granted for a period of 1 year. For further import after 1 year, it has to be registered by full dossier submission under the registration criteria. Once registered by submitting full dossier then it will be added to the registered product list. TA Temporary Approvals These are the Products approved based on physicians requisition forms submitted by clinicians, and these products are in generic name and Pre Authorization has to be taken prior to import.These products will be kept as approved products for a period of 1 year , and as pre authorization required products. If needed for further import it has to be registered by full dossier submission under the registeration criteria.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0215844 A1 Davis Et Al
    US 20090215844A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0215844 A1 Davis et al. (43) Pub. Date: Aug. 27, 2009 (54) COMPOSITIONS COMPRISING NEBVOLOL (60) Provisional application No. 60/577,423, filed on Jun. 4, 2004. (75) Inventors: Eric Davis, Morgantown, WV (US); John O'Donnell, Morgantown, WV (US); Peter Publication Classification Bottini, Morgantown, WV (US) (51) Int. Cl. A63L/353 (2006.01) Correspondence Address: A6II 3/40 (2006.01) FROST BROWN TODD, LLC A6II 3/4I (2006.01) 2200 PNCCENTER, 201 E. FIFTH STREET CINCINNATI, OH 45202 (US) (52) U.S. Cl. .......... 514/381: 514/456; 514/412: 514/423 (73) Assignee: Mylan Laboratories, Inc., Morgantown, WV (US) (57) ABSTRACT (21) Appl. No.: 12/366,866 Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart (22) Filed: Feb. 6, 2009 failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition Related U.S. Application Data comprising nebivolol and at least one other active agent, (62) Division of application No. 1 1/141,235, filed on May wherein the at least one other active agent is a cardiovascular 31, 2005. agent. Patent Application Publication Aug. 27, 2009 Sheet 1 of 4 US 2009/0215844 A1 Figure 1 50 Black Nebivolol (1.0 M) 500 white + tiebivoloi (1.0 (i)} s Black, Untreated S Swhite, untreated . 9 400 S 350. g 300 5 250 O 200 2. Untreated 1.0 Ramipriat Treatment (um) 'p < 0.05 and tip- 0.01 vs preincubation with nei olo alone (n =6) Patent Application Publication Aug.
    [Show full text]
  • Research on Identification of Chemical Status of Surface Water Bodies of the Dniester River Basin
    ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš Research on identification of chemical status of surface water bodies of the Dniester river basin Final report Project No 538063 Environmental Institute, s.r.o., Okružná 784/42, 972 41 Koš, Slovakia July 2019 Research on identification of chemical status of surface water bodies of the Dniester river basin ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš Table of contents Executive summary ........................................................................................ 4 1. Sampling points – characteristics ............................................................. 5 2. Metals in surface water and sediment samples ....................................... 7 2.1. Introduction ..................................................................................................................... 7 2.2. Methods .......................................................................................................................... 7 2.3. Surface water samples .................................................................................................... 7 2.4. Sediment samples ........................................................................................................... 8 3. Target, suspect and non-target screening surface water, biota and sediment samples by LC-HR-MS and LC-MS/MS techniques in the Dniester River Basin .................................................................................................... 11 3.1. Introduction ..................................................................................................................
    [Show full text]
  • Novel Modulation of Adenylyl Cyclase Type 2 Jason Michael Conley Purdue University
    Purdue University Purdue e-Pubs Open Access Dissertations Theses and Dissertations Fall 2013 Novel Modulation of Adenylyl Cyclase Type 2 Jason Michael Conley Purdue University Follow this and additional works at: https://docs.lib.purdue.edu/open_access_dissertations Part of the Medicinal-Pharmaceutical Chemistry Commons Recommended Citation Conley, Jason Michael, "Novel Modulation of Adenylyl Cyclase Type 2" (2013). Open Access Dissertations. 211. https://docs.lib.purdue.edu/open_access_dissertations/211 This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries. Please contact [email protected] for additional information. Graduate School ETD Form 9 (Revised 12/07) PURDUE UNIVERSITY GRADUATE SCHOOL Thesis/Dissertation Acceptance This is to certify that the thesis/dissertation prepared By Jason Michael Conley Entitled NOVEL MODULATION OF ADENYLYL CYCLASE TYPE 2 Doctor of Philosophy For the degree of Is approved by the final examining committee: Val Watts Chair Gregory Hockerman Ryan Drenan Donald Ready To the best of my knowledge and as understood by the student in the Research Integrity and Copyright Disclaimer (Graduate School Form 20), this thesis/dissertation adheres to the provisions of Purdue University’s “Policy on Integrity in Research” and the use of copyrighted material. Approved by Major Professor(s): ____________________________________Val Watts ____________________________________ Approved by: Jean-Christophe Rochet 08/16/2013 Head of the Graduate Program Date i NOVEL MODULATION OF ADENYLYL CYCLASE TYPE 2 A Dissertation Submitted to the Faculty of Purdue University by Jason Michael Conley In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy December 2013 Purdue University West Lafayette, Indiana ii For my parents iii ACKNOWLEDGEMENTS I am very grateful for the mentorship of Dr.
    [Show full text]
  • WO 2014/170786 Al 23 October 2014 (23.10.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/170786 Al 23 October 2014 (23.10.2014) P O P C T (51) International Patent Classification: 06419 (US). MAGUIRE, Bruce; 17 Waterhouse Lane, C07D 401/14 (2006.01) C07D 471/04 (2006.01) Chester, Connecticut 06412 (US). MCCLURE, Kim F.; C07D 413/14 (2006.01) C07D 487/04 (2006.01) 12 Willow Drive, Mystic, Connecticut 06355 (US). A61K 31/4725 (2006.01) A61P 7/00 (2006.01) PETERSEN, Donna N.; 107 Forsyth Road, Salem, Con A61K 31/519 (2006.01) necticut 06420 (US). PIOTROWSKI, David W.; 19 Beacon Hill Drive, Waterford, Connecticut 06385 (US). (21) International Application Number: PCT/IB20 14/060407 (74) Agent: OLSON, A. Dean; Pfizer Inc., Eastern Point Road MS8260-2141, Groton, CT 06340 (US). (22) International Filing Date: 3 April 2014 (03.04.2014) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (25) Filing Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (26) Publication Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 61/812,864 17 April 2013 (17.04.2013) US KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/880,336 20 September 2013 (20.09.2013) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/898,667 1 November 2013 (01.
    [Show full text]
  • Benefits and Harms of Treating Blood Pressure in Older Adults: a Systematic Review and Meta-Analysis
    Department of Veterans Affairs Health Services Research & Development Service Evidence-based Synthesis Program Benefits and Harms of Treating Blood Pressure in Older Adults: A Systematic Review and Meta-analysis April 2016 Prepared for: Investigators: Department of Veterans Affairs Principal Investigators: Veterans Health Administration Jessica Weiss, MD Quality Enhancement Research Initiative Devan Kansagara, MD, MCR Health Services Research & Development Service Co-Investigators: Washington, DC 20420 Amy Kerfoot, MD Prepared by: Michele Freeman, MPH Makalapua Motu’apuaka, BS Evidence-based Synthesis Program (ESP) Rochelle Fu, PhD Portland VA Health Care System Allison Low, BA Portland, OR Robin Paynter, MLIS Devan Kansagara, MD, MCR, Director Karli Kondo, PhD 4 Benefits and Harms of Treating Blood Pressure in Older Adults Evidence-based Synthesis Program PREFACE The VA Evidence-based Synthesis Program (ESP) was established in 2007 to provide timely and accurate syntheses of targeted healthcare topics of particular importance to clinicians, managers, and policymakers as they work to improve the health and healthcare of Veterans. QUERI provides funding for four ESP Centers, and each Center has an active University affiliation. Center Directors are recognized leaders in the field of evidence synthesis with close ties to the AHRQ Evidence-based Practice Centers. The ESP is governed by a Steering Committee comprised of participants from VHA Policy, Program, and Operations Offices, VISN leadership, field-based investigators, and others as designated appropriate by QUERI/HSR&D. The ESP Centers generate evidence syntheses on important clinical practice topics. These reports help: · Develop clinical policies informed by evidence; · Implement effective services to improve patient outcomes and to support VA clinical practice guidelines and performance measures; and · Set the direction for future research to address gaps in clinical knowledge.
    [Show full text]
  • (12) United States Patent (Io) Patent No.: US 9,526,824 B2 Ferrari Et Al
    1111111111111111111111111111111111111111111111111111111111111111111111 (12) United States Patent (io) Patent No.: US 9,526,824 B2 Ferrari et al. (45) Date of Patent: Dec. 27, 2016 (54) NANOCHANNELED DEVICE AND RELATED (52) U.S. Cl. METHODS CPC .............. A61M 5/00 (2013.01); A61K 9/0097 (2013.01); A61M37/00 (2013.01); (71) Applicants:The Board of Regents of the (Continued) University of Texas System, Austin, TX (US); The Ohio State University (58) Field of Classification Search Research Foundation, Columbus, OH CPC ............. B81C 1/00444; B81C 1/00476; B81C (US) 1/00119; BO1D 67/0034; YIOS 148/05 (Continued) (72) Inventors: Mauro Ferrari, Houston, TX (US); Xuewu Liu, Sugar Land, TX (US); (56) References Cited Alessandro Grattoni, Houston, TX (US); Daniel Fine, Austin, TX (US); U.S. PATENT DOCUMENTS Randy Goodall, Austin, TX (US); Sharath Hosali, Austin, TX (US); 3,731,681 A 5/1973 Blackshear et al. Ryan Medema, Pflugerville, TX (US); 3,921,636 A 11/1975 Zaffaroni Lee Hudson, Elgin, TX (US) (Continued) (73) Assignees: The Board of Regents of the FOREIGN PATENT DOCUMENTS University of Texas System, Austin, TX (US); The Ohio State University CN 1585627 2/2005 Research Foundation, Columbus, OH DE 10 2006 014476 7/2007 (US) (Continued) (*) Notice: Subject to any disclaimer, the term of this OTHER PUBLICATIONS patent is extended or adjusted under 35 U.S.C. 154(b) by 784 days. "The Economic Costs of Drug Abuse in the United States," www. whitehousedrugpolicy.gov, Sep. 2001. (21) Appl. No.: 13/875,871 (Continued) (22) Filed: May 2, 2013 Primary Examiner Binh X Tran (65) Prior Publication Data (74) Attorney, Agent, or Firm Parker Highlander PLLC US 2013/0240483 Al Sep.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0018933 A1 Vaya Et Al
    US 20060018.933A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0018933 A1 Vaya et al. (43) Pub. Date: Jan. 26, 2006 (54) NOVELDRUG DELIVERY SYSTEM (30) Foreign Application Priority Data Aug. 5, 2002 (IN)................................. 698/MUM/2002 (76) Inventors: Navin Vaya, Gujarat (IN); Rajesh Aug. 5, 2002 (IN). ... 696/MUM/2003 Singh Karan, Gujarat (IN); Sunil Jan. 22, 2003 (IN)................................... 81/MUM/2003 Sadanand Nadkarni, Gujarat (IN); Vinod Kumar Gupta, Gujarat (IN) Publication Classification (51) Int. Cl. Correspondence Address: A6IK 9/24 (2006.01) HEDMAN & COSTIGAN P.C. A6IK 9/00 (2006.01) 1185 AVENUE OF THE AMERICAS (52) U.S. Cl. ............................................ 424/400; 424/472 NEW YORK, NY 10036 (US) (57) ABSTRACT (21) Appl. No.: 11/134,631 A novel modified release dosage form comprising of a high (22) Filed: May 19, 2005 Solubility active ingredient, which utilizes dual retard tech nique to effectively reduce the quantity of release controlling Related U.S. Application Data agents. Present invention can optionally comprise addition ally another active ingredient as an immediate release form (63) Continuation-in-part of application No. 10/630,348, or modified release form. Present invention also relates to a filed on Jul. 29, 2003. process for preparing the Said formulation. Patent Application Publication Jan. 26, 2006 Sheet 1 of 5 US 2006/0018933 A1 FIGURE 1 (a) FIGURE 1 (b) Patent Application Publication Jan. 26, 2006 Sheet 2 of 5 US 2006/0018933 A1 FIGURE 2 12 O OO 8 O 6 O 4 O 2 O ----------- O 2 4. 6 8 1 O 2 14 6 18 2O 22 24 26 Time (hour ) Patent Application Publication Jan.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,071,075 B2 Reed Et Al
    USO08071075B2 (12) United States Patent (10) Patent No.: US 8,071,075 B2 Reed et al. (45) Date of Patent: *Dec. 6, 2011 (54) DERMAL PENETRATION ENHANCERS AND A618/26 (2006.01) DRUG DELIVERY SYSTEMIS INVOLVING A618/02 (2006.01) THE SAME A69/70 (2006.01) (75) Inventors: Barry Leonard Reed, Strathmore (AU); A61N L/30 (2006.01) Timothy Matthias Morgan, Parkville (52) U.S. Cl. .............. 424/47; 424/59: 424/68; 424/401; (AU); Barrie Charles Finnin, Glen Iris 424/449; 604/20 (AU) (58) Field of Classification Search ........................ None See application file for complete search history. (73) Assignee: Acrux DDS Pty Ltd., West Melbourne, Victoria (AU) (56) References Cited (*) Notice: Subject to any disclaimer, the term of this U.S. PATENT DOCUMENTS patent is extended or adjusted under 35 3,989,816 A 11/1976 Rajadhyaksha U.S.C. 154(b) by 758 days. 4,299,826 A 11/1981 Luedders This patent is Subject to a terminal dis (Continued) claimer. FOREIGN PATENT DOCUMENTS (21) Appl. No.: 11/905,926 AU 30258/89 9, 1989 (Continued) (22) Filed: Oct. 5, 2007 OTHER PUBLICATIONS (65) Prior Publication Data “Expert opinion of therapeutic patents' Stella et al., 2004 14(3): US 2008/O152597 A1 Jun. 26, 2008 277-280.* Related U.S. Application Data (Continued) (60) Continuation of application No. 10/759,303, filed on Primary Examiner — Ernst Arnold Jan. 20, 2004, now Pat. No. 7,438,203, which is a continuation-in-part of application No. 09/910,780, Assistant Examiner — Hong Yu filed on Jul. 24, 2001, now Pat.
    [Show full text]
  • Drug-Resin Complexes Stabilized by Chelating Agents
    ^ ^ ^ ^ I ^ ^ ^ ^ ^ ^ II ^ II ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ I ^ European Patent Office Office europeen des brevets EP0 911 039 A2 EUROPEAN PATENT APPLICATION (43) Date of publication: (51) |nt Cl.e: A61K 47/48 28.04.1999 Bulletin 1999/17 (21) Application number: 98201125.6 (22) Date of filing: 08.04.1998 (84) Designated Contracting States: (72) Inventor: Eichman, Martin AT BE CH DE DK ES Fl FR GB GR IE IT LI LU MC Fairport, New York 14450 (US) NL PT SE Designated Extension States: (74) Representative: AL LT LV MK RO SI Smulders, Theodorus A.H.J., Ir. et al Vereenigde Octrooibureaux (30) Priority: 16.04.1997 US 834359 Nieuwe Parklaan 97 2587 BN 's-Gravenhage (NL) (71) Applicant: Medeva Pharmaceutical Manufacturing, Inc. Rochester, New York 14623-1710 (US) (54) Drug-resin complexes stabilized by chelating agents (57) The invention provides a pharmaceutical com- solid or a gel. The invention also provides a method of position comprising a drug-resin complex and a chelat- making such a composition and a method for improving ing agent in which the composition is in the form of a the stability of a pharmaceutical composition. CM < O) CO o O) o a. LU Printed by Jouve, 75001 PARIS (FR) EP0 911 039 A2 Description FIELD OF THE INVENTION 5 [0001] The present invention relates generally to pharmaceutical compositions. The invention particularly relates to drug-resin complexes stabilized by chelating agents and a method of making these drug-resin complexes. Another aspect of the invention is a method for using such stabilized drug-resin complexes in the treatment of patients.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,354,116 B2 Carter Et Al
    USOO8354116B2 (12) United States Patent (10) Patent No.: US 8,354,116 B2 Carter et al. (45) Date of Patent: Jan. 15, 2013 (54) BIFUNCTIONAL SYNTHETIC MOLECULES Chinese Office Action, with English translation, dated Apr. 20, 2011 in corresponding foreign patent application No. CN 200880 103516. 1. (75) Inventors: Stephen G. Carter, Andover, MA (US); Wang, Xiu Q., et al., “Erythropoietin Depresses Nitric Oxide Kanu Patel, Londonderry, NH (US); Synthase Expression by Human Endothelial Cells'. Hypertension. Zhen Zhu, Tewksbury, MA (US); Lixin 1999, 33:894-899. Qiao, Tewksbury, MA (US) Krapf, Reto, et al., “Arterial Hypertension Induced by Erythropoietin and Erythropoiesis-Stimulating Agents (ESA). Clinical Journal of the American Society of Nephrology, Feb. 2009, vol. 4 No. 2, pp. (73) Assignee: BioChemics, Inc., Danvers, MA (US) 470-480 + refs. Canadian Communication dated Mar. 8, 2012 in corresponding (*) Notice: Subject to any disclaimer, the term of this Canadian patent application No. CA 2690357. patent is extended or adjusted under 35 Canadian Communication dated Jul. 25, 2011 in corresponding U.S.C. 154(b) by 1247 days. Canadian patent application No. CA 2690357. Chinese Communication, with English translation, dated Mar. 28. (21) Appl. No.: 11/820,172 2012 in corresponding Chinese Patent Application No. 200880 1035161, 11 pages. (22) Filed: Jun. 18, 2007 * cited by examiner (65) Prior Publication Data Primary Examiner — Robert A Wax US 2008/0312296A1 Dec. 18, 2008 Assistant Examiner — Melissa Mercier (51) Int. Cl. (74) Attorney, Agent, or Firm — Nields, Lemack & Frame, A6 IK9/00 (2006.01) LLC A6 IK 8/02 (2006.01) (52) U.S. Cl.
    [Show full text]